Literature DB >> 3919659

Demonstration and identification of monoclonal proteins in the urine of patients with Sjögren's syndrome.

H M Moutsopoulos, R Costello, A A Drosos, A K Mavridis, N M Papadopoulos.   

Abstract

Fresh sera and concentrated urine from 17 patients with primary Sjögren's syndrome (SS) were fractionated by high-resolution agarose electrophoresis to investigate the presence of monoclonal immunoglobulins or their components. Homogeneous protein bands were found in the gamma-globulin region in 47% of serum samples and 76% of urine specimens of all patients tested. These monoclonal proteins were detected more often in patients with extraglandular SS (77% in serum, 100% in the urine) than in patients with glandular SS (14% in serum, 43% in the urine). Immunofixation electrophoresis showed that the majority of these monoclonal proteins were free kappa or lambda light chains. Fractionation of unconcentrated parotid salivas from five SS patients failed to reveal the presence of monoclonal light chains or immunoglobulins. The present findings further substantiate our previous observation that a monoclonal process coexists with the polyclonal activation in SS patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3919659      PMCID: PMC1001583          DOI: 10.1136/ard.44.2.109

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

1.  Differentiation of pathological conditions by visual evaluation of serum protein electrophoretic patterns.

Authors:  N M Papadopoulos; J A Kintzios
Journal:  Proc Soc Exp Biol Med       Date:  1967-07

2.  Evidence that the malignant lymphoma of Sjögren's syndrome is a monoclonal B-cell neoplasm.

Authors:  J Zulman; R Jaffe; N Talal
Journal:  N Engl J Med       Date:  1978-11-30       Impact factor: 91.245

3.  Incidence of gamma-globulin banding in a healthy population by high-resolution electrophoresis.

Authors:  N M Papadopoulos; R J Elin; D M Wilson
Journal:  Clin Chem       Date:  1982-04       Impact factor: 8.327

4.  Immunofixation: application to the identification of "difficult" monoclonal components.

Authors:  E Pascali; A Pezzoli; A Chiarandini
Journal:  Clin Chem       Date:  1982-06       Impact factor: 8.327

5.  Immunofixation electrophoresis and electrofocusing.

Authors:  A M Johnson
Journal:  Clin Chem       Date:  1982-08       Impact factor: 8.327

6.  Increased risk of lymphoma in sicca syndrome.

Authors:  S S Kassan; T L Thomas; H M Moutsopoulos; R Hoover; R P Kimberly; D R Budman; J Costa; J L Decker; T M Chused
Journal:  Ann Intern Med       Date:  1978-12       Impact factor: 25.391

7.  Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis.

Authors:  H M Moutsopoulos; B L Webber; T P Vlagopoulos; T M Chused; J L Decker
Journal:  Am J Med       Date:  1979-05       Impact factor: 4.965

8.  Sjögren's syndrome (Sicca syndrome): current issues.

Authors:  H M Moutsopoulos; T M Chused; D L Mann; J H Klippel; A S Fauci; M M Frank; T J Lawley; M I Hamburger
Journal:  Ann Intern Med       Date:  1980-02       Impact factor: 25.391

9.  High incidence of free monoclonal lambda light chains in the sera of patients with Sjogren's syndrome.

Authors:  H M Moutsopoulos; A D Steinberg; A S Fauci; H C Lane; N M Papadopoulos
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

10.  Non-IgM monoclonal gammopathy in patients with Sjögren's syndrome.

Authors:  S Sugai; S Konda; Y Shoraski; T Murayama; T Nishikawa
Journal:  Am J Med       Date:  1980-06       Impact factor: 4.965

View more
  13 in total

Review 1.  Rheumatoid arthritis, malignancy, and paraproteins.

Authors:  C Kelly; H Sykes
Journal:  Ann Rheum Dis       Date:  1990-09       Impact factor: 19.103

2.  Renal tubular acidosis in primary Sjögren's syndrome.

Authors:  K C Siamopoulos; M Elisaf; A A Drosos; A A Mavridis; H M Moutsopoulos
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

3.  Analysis of autoantibodies to recombinant La (SS-B) peptides in systemic lupus erythematosus and primary Sjogren's syndrome.

Authors:  P Bini; J L Chu; C Okolo; K Elkon
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

4.  Evidence for oligoclonal B cell expansion in the peripheral blood of patients with rheumatoid arthritis.

Authors:  D A Fox; B R Smith
Journal:  Ann Rheum Dis       Date:  1986-12       Impact factor: 19.103

5.  Urinary monoclonal free light chains in primary Sjögren's syndrome: an aid to the diagnosis of malignant lymphoma.

Authors:  M T Walters; F K Stevenson; A Herbert; M I Cawley; J L Smith
Journal:  Ann Rheum Dis       Date:  1986-03       Impact factor: 19.103

6.  Lupus/Sjögren's autoantibody specificities in sera with paraproteins.

Authors:  A L Sestak; J B Harley; S Yoshida; M Reichlin
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

7.  Sjögren's syndrome, vasculitis, and cryoglobulinaemia associated with a monoclonal IgM (kappa) paraprotein with rheumatoid factor activity.

Authors:  S Fitzgerald; N P Hurst; P R Pannall
Journal:  Ann Rheum Dis       Date:  1987-06       Impact factor: 19.103

8.  Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome.

Authors:  J-E Gottenberg; F Aucouturier; J Goetz; C Sordet; I Jahn; M Busson; J-M Cayuela; J Sibilia; X Mariette
Journal:  Ann Rheum Dis       Date:  2006-03-28       Impact factor: 19.103

9.  Prognostic significance of paraproteinaemia in rheumatoid arthritis.

Authors:  C Kelly; G Baird; H Foster; H Hosker; I Griffiths
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

Review 10.  Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients.

Authors:  Michael Voulgarelis; Fotini N Skopouli
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.